BVF Inc. IL grew its position in Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 77.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,730,983 shares of the company’s stock after buying an additional 2,930,000 shares during the quarter. Kura Oncology makes up approximately 3.0% of BVF Inc. IL’s portfolio, making the stock its 8th largest position. BVF Inc. IL owned approximately 9.84% of Kura Oncology worth $82,320,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in KURA. Nisa Investment Advisors LLC boosted its holdings in shares of Kura Oncology by 147.3% during the first quarter. Nisa Investment Advisors LLC now owns 2,325 shares of the company’s stock worth $28,000 after purchasing an additional 1,385 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Kura Oncology by 386.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 4,089 shares of the company’s stock worth $50,000 after purchasing an additional 3,248 shares during the period. Denali Advisors LLC boosted its holdings in shares of Kura Oncology by 136.8% during the first quarter. Denali Advisors LLC now owns 9,000 shares of the company’s stock worth $110,000 after purchasing an additional 5,200 shares during the period. Point72 Middle East FZE acquired a new stake in shares of Kura Oncology during the fourth quarter worth approximately $115,000. Finally, Gyon Technologies Capital Management LP acquired a new stake in shares of Kura Oncology during the fourth quarter worth approximately $119,000.
In related news, Director Thomas Malley acquired 50,000 shares of the stock in a transaction dated Friday, June 16th. The shares were acquired at an average price of $11.50 per share, for a total transaction of $575,000.00. Following the completion of the purchase, the director now owns 139,557 shares in the company, valued at approximately $1,604,905.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.40% of the company’s stock.
Analyst Ratings Changes
Kura Oncology Trading Down 1.5 %
NASDAQ:KURA opened at $10.00 on Tuesday. Kura Oncology, Inc. has a 12 month low of $9.28 and a 12 month high of $17.27. The firm has a market cap of $742.40 million, a price-to-earnings ratio of -4.88 and a beta of 0.77. The company has a quick ratio of 20.32, a current ratio of 20.32 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average is $10.42 and its 200-day moving average is $11.32.
Kura Oncology (NASDAQ:KURA – Get Free Report) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.04. Equities analysts anticipate that Kura Oncology, Inc. will post -2.18 EPS for the current year.
Kura Oncology Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.
- Five stocks we like better than Kura Oncology
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- An Electrifying New Upgrade for Tesla Leads the Market Higher
- The How And Why of Investing in Oil Stocks
- Oil Jumps, 2 Plastic Stocks About To Become Value Plays
- How to Invest in the FAANG Stocks
- The Top 5 Analysts Calls in September
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.